314 related articles for article (PubMed ID: 25841300)
21. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
22. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.
Karyekar CS; Ravichandran S; Allen E; Fleming D; Frederich R
Clin Interv Aging; 2013; 8():419-30. PubMed ID: 23626461
[TBL] [Abstract][Full Text] [Related]
23. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Rosenstock J; Sankoh S; List JF
Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
[TBL] [Abstract][Full Text] [Related]
24. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Handelsman Y; Mathieu C; Del Prato S; Johnsson E; Kurlyandskaya R; Iqbal N; Garcia-Sanchez R; Rosenstock J
Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
[TBL] [Abstract][Full Text] [Related]
25. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
Mathieu C; Herrera Marmolejo M; González González JG; Hansen L; Chen H; Johnsson E; Garcia-Sanchez R; Iqbal N
Diabetes Obes Metab; 2016 Nov; 18(11):1134-1137. PubMed ID: 27385192
[TBL] [Abstract][Full Text] [Related]
28. Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus.
Chen K; Zhuo T; Wang J; Mei Q
Metab Syndr Relat Disord; 2018 Sep; 16(7):336-341. PubMed ID: 29912623
[TBL] [Abstract][Full Text] [Related]
29. A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment.
Wang Z; Wang J; Hu J; Chen Y; Dong B; Wang Y
Life Sci; 2021 Jun; 274():119069. PubMed ID: 33460667
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study.
Gu W; Liang L; Wang S; Wang Y; Wu Y; Tian J; Yang G; Piao C; Li Y; Yin J; Xin X; Tan X; Ning G; Wang W;
J Diabetes; 2016 Nov; 8(6):809-815. PubMed ID: 26676908
[TBL] [Abstract][Full Text] [Related]
31. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
[TBL] [Abstract][Full Text] [Related]
32. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Cook W; Minervini G; Bryzinski B; Hirshberg B
Postgrad Med; 2014 Oct; 126(6):19-32. PubMed ID: 25414932
[TBL] [Abstract][Full Text] [Related]
33. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
[TBL] [Abstract][Full Text] [Related]
34. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.
Fonseca V; Zhu T; Karyekar C; Hirshberg B
Diabetes Obes Metab; 2012 Apr; 14(4):365-71. PubMed ID: 22192246
[TBL] [Abstract][Full Text] [Related]
35. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.
Göke B; Gallwitz B; Eriksson JG; Hellqvist Å; Gause-Nilsson I
Int J Clin Pract; 2013 Apr; 67(4):307-16. PubMed ID: 23638466
[TBL] [Abstract][Full Text] [Related]
36. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
Garnock-Jones KP
Drugs; 2017 Mar; 77(3):319-330. PubMed ID: 28176222
[TBL] [Abstract][Full Text] [Related]
37. Saxagliptin (Onglyza) for type 2 diabetes.
Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
[No Abstract] [Full Text] [Related]
38. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
[TBL] [Abstract][Full Text] [Related]
40. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Del Prato S; Rosenstock J; Garcia-Sanchez R; Iqbal N; Hansen L; Johnsson E; Chen H; Mathieu C
Diabetes Obes Metab; 2018 Jun; 20(6):1542-1546. PubMed ID: 29446523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
